Coverage
-
November 25, 2014
Novartis AG on Monday ducked a putative class action alleging it broke New Jersey consumer fraud laws by charging more for a migraine medicine than for another chemically identical painkiller when a federal judge ruled that, while strategic, the company's pricing scheme wasn't illegal.
1 other articles on this case.
View all »